[Therapeutic effect of pyridylcarbinolic ester of clofibric acid on the changes of the lipid and fibrinolytic picture in arteriosclerotic patients].
D000368:Aged; D001161:Arteriosclerosis / Q000097:blood / Q000188:drug therapy*; D002784:Cholesterol / Q000097:blood; D002986:Clinical Trials as Topic; D002994:Clofibrate / Q000494:pharmacology / Q000627:therapeutic use*; D004341:Drug Evaluation; D005260:Female; D005342:Fibrinolysis / Q000187:drug effects*; D006801:Humans; D002537:Intracranial Arteriosclerosis / Q000188:drug therapy; D008055:Lipids / Q000097:blood*; D008074:Lipoproteins / Q000097:blood; D008297:Male; D008875:Middle Aged; D011725:Pyridines / Q000494:pharmacology / Q000627:therapeutic use*; D013916:Thrombelastography; D014280:Triglycerides / Q000097:blood
D008055:Lipids; D008074:Lipoproteins; D011725:Pyridines; D014280:Triglycerides; D002784:Cholesterol; D002994:Clofibrate
Azione terapeutica dell'estere piridilcarbinolico dell'acido clofibrico sulle alterazioni del quadro lipidico e fibrinolitico in pazienti arteriosclerotici